The addition of the FLT3 inhibitor Quizartinib to pre-transplant chemotherapy, in combination with post-transplant maintenance, will be studied in FLT3+ pediatric patients within the CHIP-AML protocol as part of a linked “Quizartinib” trial (recently approved and currently recruiting). Here, FLT3 is linked to acute myeloid leukemia.